| Serial Number | 79378525 |
| Word Mark | POLYPEPTIDE |
| Filing Date | Friday, May 5, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 24, 2024 |
| Registration Number | 7616806 |
| Registration Date | Tuesday, December 24, 2024 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, October 22, 2024 |
| Goods and Services | Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing |
| Description of Mark | The mark consists of a stylized atomic model in green. To the right of this design is the wording "POLYPEPTIDE" in black font. The white in the mark is background only and is not claimed as a feature of the mark. |
| Goods and Services | Synthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncology, neurology, rare diseases for the treatment of genetic disorders, neurodegenerative diseases and cancer; pharmaceutical and veterinary preparations, namely, synthetic peptides for pharmaceutical and veterinary purposes for fertility control in animals, induction of ovulation in mares, castration of dogs, facilitation of parturition in livestock; biological preparations for medical and veterinary purposes, namely, polypetide biochemicals for medical and veterinary purposes for oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; medicated dandruff and hair loss shampoos, medicated hair lotions for treating dandruff hair loss and hair damage, medicated soap cleansers for the skin, and medicated cosmetics, namely creams for treating acne, irritated, itching, and inflamed skin, repairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressings, namely, medical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines |
| Goods and Services | Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices |
| Indication of Colors claimed | The color(s) green and black is/are claimed as a feature of the mark. |
| Goods and Services | Advertising services; business administration; business management; providing office function |
| Goods and Services | Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes |
| NOT AVAILABLE | "POLYPEPTIDE" |
| Goods and Services | Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucelotide manufacturing |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 18, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 003 - Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. |
| US Class Codes | 001, 004, 006, 050, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 18, 2023 |
| Primary Code | 003 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 18, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 18, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 18, 2023 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 18, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Polypeptide Laboratories Holding (PPL) AB |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | SE |
| Party Name | Polypeptide Laboratories Holding (PPL) AB |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | SE |
| Party Name | Polypeptide Laboratories Holding (PPL) AB |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | SE |
| Event Date | Event Description |
| Monday, September 18, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 14, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, September 22, 2023 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, January 31, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, February 7, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, February 28, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, March 19, 2024 | REFUSAL PROCESSED BY IB |
| Wednesday, August 28, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, August 28, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, August 28, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, February 6, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, February 28, 2024 | REFUSAL PROCESSED BY MPU |
| Monday, September 16, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Monday, September 16, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, September 16, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, September 16, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Monday, September 16, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 2, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 22, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 22, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 24, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, December 24, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |